Predicting Agents That Can Overcome 5-FU Resistance in Colorectal Cancers via Pharmacogenomic Analysis

5-Fluorouracil (5-FU) is one of several chemotherapeutic agents in clinical use as a standard of care to treat colorectal cancers (CRCs). As an antimetabolite, 5-FU inhibits thymidylate synthase to disrupt the synthesis and repair of DNA and RNA. However, only a small proportion of patients benefit...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Tsui-Chin, Peng, Kuan-Chieh, Kuo, Tzu-Ting, Lin, Li-Chun, Liu, Bai-Chia, Ye, Shu-Ping, Chu, Chien-Chou, Hsia, Shih-Min, Chang, Hsin-Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389646/
https://www.ncbi.nlm.nih.gov/pubmed/34440086
http://dx.doi.org/10.3390/biomedicines9080882

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389646/
https://www.ncbi.nlm.nih.gov/pubmed/34440086
http://dx.doi.org/10.3390/biomedicines9080882

Ejemplares similares